Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 655-659 , 5 November 2009

The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients

  • Criscely L. Go

      Affiliations

    • Department of Neurology and Psychiatry, University of Santo Tomas Hospital, 3001 Medical Arts Building, Manila 1008, Philippines
    • ,
  • Raymond L. Rosales

      Affiliations

    • Department of Neurology and Psychiatry, University of Santo Tomas Hospital, 3001 Medical Arts Building, Manila 1008, Philippines
    • Corresponding Author InformationCorresponding author. Fax: +63 2 712 6348.
    • ,
  • Rico J. Caraos

      Affiliations

    • National Center for Mental Health, Mandaluyong City, Philippines
    • ,
  • Hubert H. Fernandez

      Affiliations

    • Department of Neurology, University of Florida McKnight Brain Institute, Gainesville, FL, USA

Received 30 September 2008 ,Revised 25 February 2009 ,Accepted 26 February 2009.

References 

  1. Fernandez H, Friedman JH. Classification and treatment of tardive syndromes. Neurologist. 2003;9:16–27
  2. Chong SA, Sachdev P. The epidemiology of tardive dyskinesia. In:  Sethi K editors. Drug induced movement disorders. Ch. 3:New York: Marcel Dekker; 2004;p. 33–37
  3. Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol. 2002;22:26–30
  4. Woerner MG, Alvir MJ, Saltz BL, Liebermann JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521–1528
  5. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(Suppl 14):27–32
  6. Chiu HF, Wing YK, Kwong PK. Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong. Acta Psychiatr Scand. 1993;87:266–268
  7. Krueger RB, Sackheim HA. Electroconvulsive therapy and schizophrenia. In:  Hirsh SR,  Weinberger DR editor. Schizophrenia. England: Blackwell Science; 1995;p. 305–545
  8. Fahn, S. A comprehensive review of movement disorders for the clinical practitioner. the tardive syndromes: phenomenology, concepts on pathophysiology, and treatment and other neuroleptic-induced syndromes. The Movement Disorders 14th Course. Aspen, CO. 2004. p. 191-247.
  9. Janno S, Holi M. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenic in patients. Am J Psychiatry. 2004;161:160–163
  10. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487
  11. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris J, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low dose treatment with typical neuroleptics in older patients. Am J Psychiatry. 1999;156:309–311
  12. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of literature. Schizophr Bull. 1992;18:701–710
  13. Lehman AF, Steinwachs DM. At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) Treatment recommendations. Schizophr Bull. 1998;24:1–10
  14. Yassa R, Nair NVP, Jeste DV. Neuroleptic induced movement disorders. a comprehensive survey. Cambridge University Press; 1997;p. 257-9
  15. Ananda K, Pandurangi , Yekeen A. Tardive dyskinesia in non-western countries: A review. Euro Arch Psychiatry Clin Neurosci. 1995;246:47–52
  16. Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aus NZ J Psychiatry. 1991;25:119–122
  17. Osman A, Marghalani M, Turkistani IY, Al-Swaf M, Bin Sadiq B. Neuroleptic-induced tardive dyskinesia among Arab psychotic patients. East Mediterr Health J. 2007;13:625–632
  18. Lerner V, Libov I, Kaptsan A, Miodownik C, Dwolatzky T, Levine J. The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci. 2007;4:20–28
  19. Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, et al. Tardive dyskinesia in India: a prevalence study. J Clin Psychopharmacol. 1982;2:341–344
  20. Wegner J, Kane J. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry. 1982;139:368–369
  21. Klawans H, Tanner D, Barr A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol. 1984;7:153–159
  22. Casey D, Povlsen U, Meidahl B. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years of continuing treatment. Psychopharmacol Bull. 1986;22:250–253
  23. Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985;34:211–219
  24. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159–169
  25. Muscettola G. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1997;87:29–36
  26. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324–1333
  27. Fernandez H, Krupp B, Friedman J. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001;56:805–807
  28. Chong S, Tan EC, Tan CH. Mythily. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci. 2003;28:185–189
  29. Fernandez HH, McCown K, Romrell J, Trieschmann ME, Friedman JH, Jacobson CE, et al. New-onset diabetes mellitus among parkinsonian patients treated with long-term quetiapine. Drug Target Insights. 2008;3:27–29
  30. Fernandez HH, Friedman JH, Lansang MC, Factor SA, Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord. 2004;10:439–441

PII: S1353-8020(09)00060-1

doi: 10.1016/j.parkreldis.2009.02.015

Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 655-659 , 5 November 2009

Article Tools

* Image Usage & Resolution